Atlas Trials

Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

Clinical trial NCT02626364 · COMPLETED

Trial details

NCT number
NCT02626364
Sponsor
Arog Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent/Refractory Glioblastoma
Start date
2016-04-01
Primary completion
2020-07-01
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.